Antiandrogens may increase mortality risk in men with CVD
Patients with CVD taking abiraterone or enzalutamide have a 43% higher risk of hospitalization, according to a recent study.
www.urologytimes.com
Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care - PubMed
In men with prostate cancer, combination therapy with LHRH agonists and anti-androgens is associated with significant increases in the risk of CHD, AMI, incident HF and hospitalized HF. Individual therapies do not appear to increase the risk of these outcomes.
pubmed.ncbi.nlm.nih.gov
I have read that RU is similar to nilutamide bicutamide which can cause permanent heart damage. Thoughts on these studys?